The Analgesic Efficacy of Transversus Abdominis Plane Block After Laparoscopic Cholecystectomy
NCT ID: NCT01046071
Last Updated: 2011-11-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
80 participants
INTERVENTIONAL
2010-03-31
2011-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
transversus abdominis plane block
transversus abdominis plane block with ropivacaine
transversus abdominis plane block
UL-guided TAP block with 20 ml of ropivacaine 0,5% bilateral, single dose.
block with saline
20 ml of isotonic saline bilateral
TAP block placebo
UL-guided TAP block with 20 ml of saline bilaterally, single dose.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
transversus abdominis plane block
UL-guided TAP block with 20 ml of ropivacaine 0,5% bilateral, single dose.
TAP block placebo
UL-guided TAP block with 20 ml of saline bilaterally, single dose.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ASA 1-3
* BMI 18-35
* Written consent
Exclusion Criteria
* Drug allergy
* Pregnancy
* Alcohol or drug abuse
* Chronic pain with consumption of opioids
* Consumption of NSAID, COX2inhibitors or paracetamol within 24 hours before the investigation
* Infection at the needle site.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Glostrup University Hospital, Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pernille Lykke Petersen
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pernille L Petersen, MD
Role: PRINCIPAL_INVESTIGATOR
Copenhagen University Hospital, Glostrup
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Glostrup University Hospital, Department of anesthesia
Glostrup Municipality, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009-017420-75
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
SM1-plp-09
Identifier Type: -
Identifier Source: org_study_id